222 related articles for article (PubMed ID: 1568289)
1. Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin.
Fournier C; Hecquet B; Bastian G; Khayat D
Cancer Chemother Pharmacol; 1992; 29(6):461-6. PubMed ID: 1568289
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of cisplatin and carboplatin used alone and in combination with the other anticancer drugs in the mouse embryo C3H10T1/2 cell line.
Hussain SS; Amer MH; Hannan MA
Chemotherapy; 1988; 34(6):504-11. PubMed ID: 2468457
[TBL] [Abstract][Full Text] [Related]
3. Platinum compounds in the treatment of advanced breast cancer.
MartÃn M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
4. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
Mandal R; Kalke R; Li XF
Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
[TBL] [Abstract][Full Text] [Related]
6. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Fujimoto S
Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin.
Heudi O; Mercier-Jobard S; Cailleux A; Allain P
Biopharm Drug Dispos; 1999 Mar; 20(2):107-16. PubMed ID: 10206326
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Orr RM; O'Neill CF; Nicolson MC; Barnard CF; Murrer BA; Giandomenico CM; Vollano JF; Harrap KR
Br J Cancer; 1994 Sep; 70(3):415-20. PubMed ID: 8080724
[TBL] [Abstract][Full Text] [Related]
9. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
[TBL] [Abstract][Full Text] [Related]
10. Mutagenicity of cisplatin and carboplatin used alone and in combination with four other anticancer drugs.
Hannan MA; al-Dakan AA; Hussain SS; Amer MH
Toxicology; 1989 Apr; 55(1-2):183-91. PubMed ID: 2652378
[TBL] [Abstract][Full Text] [Related]
11. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin.
Oprea A; Bazzazi H; Kangarloo B; Wolff JE
Anticancer Res; 2001; 21(2A):1225-9. PubMed ID: 11396168
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
14. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M
Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs.
Theile D; Kos M
Toxicol Lett; 2016 Feb; 242():47-52. PubMed ID: 26656794
[TBL] [Abstract][Full Text] [Related]
16. A comparison study on RNase A oligomerization induced by cisplatin, carboplatin and oxaliplatin.
Picone D; Donnarumma F; Ferraro G; Gotte G; Fagagnini A; Butera G; Donadelli M; Merlino A
J Inorg Biochem; 2017 Aug; 173():105-112. PubMed ID: 28511060
[TBL] [Abstract][Full Text] [Related]
17. Kinetic study on the reactions of platinum drugs with glutathione.
Hagrman D; Goodisman J; Souid AK
J Pharmacol Exp Ther; 2004 Feb; 308(2):658-66. PubMed ID: 14610218
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity and nephrotoxicity of a novel platinum complex, [1,3-bis(diphenylphosphino)propane](trans-1-dach)platinum(I I) dinitrate.
Baek MS; Rho YS; Jung JC; Chang SG; Nomura M; Miyamoto KJ
Anticancer Res; 1997; 17(2A):955-9. PubMed ID: 9137434
[TBL] [Abstract][Full Text] [Related]
19. [Antileukemic activity and development of resistance to cisplatin (CPT) and platinum (IV)-nitroxyl complex VS118].
Goncharova SA; Raevskaia TA; Iakushchenko TN; Blokhina SV; Konovalova NP; Sen' VD
Vopr Onkol; 2011; 57(3):355-8. PubMed ID: 21882607
[TBL] [Abstract][Full Text] [Related]
20. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine.
Dorie MJ; Brown JM
Cancer Chemother Pharmacol; 1997; 39(4):361-6. PubMed ID: 9025778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
